OpenAlex
PricingAboutJobs
Log inGet started
Work

SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis

HTML

Year: 2023
Type: article
Source: Metabolism
DOI: 10.1016/j.metabol.2023.155657
Authors: Yunfeng Shen, Lidan Cheng, Minxuan Xu, Wei Wang, Zhiping Wan, Haixia Xiong, Wanrong Guo, Mengyin Cai, Fen Xu
Institutions: Second Affiliated Hospital of Nanchang University, Second Hospital of Nanchang, Jiujiang University, Key Laboratory of Guangdong Province, Yangtze University, Third Affiliated Hospital of Sun Yat-sen University
Language: English

Topic: Liver Disease Diagnosis and Treatment
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: empagliflozin, SGLT2 inhibitors, miR-34a-5p, GREM2, hepatic stellate cells, liver fibrosis, non-alcoholic fatty liver disease, TGF-beta signaling, LX-2 cells, microRNA target regulation, ob/ob mice, methionine-choline-deficient diet, type 2 diabetes
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W4383340895
FWCI: 14.16
Cites: 58
Cited by: 128
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security